Dabigatran Etexilate Mesylate Pellets

Dabigatran Etexilate Mesylate Pellets

CAS No.872728-81-9
Therapeutic CategoryCardiovascular
Dosage FormOral Solids
Innovator BrandPradaxa(USA)
Registration StatusChina: A, Written Confirmation
US: DMF 36539
Japan: MF under registration
EU: CEP under application
Others: DMF
PolymorphForm I
GMPFDA(USA)/NMPA(China)/MFDS(Korea) approved
EHSISO 14001 & 45001 certified

Product Description

  • Grade: Active Pharmaceutical Ingredient(API)
  • Molecular Formula: C35H45N7O8S
  • Molecular Weight:723.839
  • Specification: EP, Enterprise Standard established according to ChP/USP/EP
  • Appearance: Powder
  • Total impurities: not more than 0.5%
  • Purity: not less than 99%
  • Residual Solvents: fully comply with ICH Q3C
  • Mutagenic impurities: fully comply with ICH M8
  • Nitrosamine assessment: available
  • Particle size: regular grade and micronized(D90<10μm)
  • Storage: Room temperature
  • Production capacity: Commercial
  • Standard Package: 1kg/bag, 5kg/bag, or according to the customer’s requirement

Applications of Dabigatran Etexilate Mesylate Pellets

  • Dabigatran, sold under the brand name Pradaxa among others, is an anticoagulant used to treat and prevent blood clots and stroke in people with atrial fibrillation. Specifically, it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. It is used as an alternative to warfarin and does not require monitoring by blood tests. In a meta analysis of 7 different studies, there was no benefit of dabigatran over warfarin in preventing ischemic stroke; however, dabigatran was associated with a lower hazard for intracranial bleeding compared with warfarin but also had a higher risk of gastrointestinal bleeding relative to warfarin. It is taken by mouth.
  • Common side effects include bleeding and gastritis. Other side effects may include bleeding around the spine and allergic reactions such as anaphylaxis. In cases of severe bleeding, it can be reversed with the antidote, idarucizumab. Use is not recommended during pregnancy or breastfeeding. Compared to warfarin it has fewer interactions with other medications. It is a direct thrombin inhibitor.
  • Dabigatran was approved for medical use in the United States in 2010. It is on the World Health Organization’s List of Essential Medicines. In 2020, it was the 306th most commonly prescribed medication in the United States, with more than 1 million prescriptions. Dabigatran is available as a generic medication.

Why Choose Us as Your Dabigatran Manufacturer?

  • As a Dabigatran manufacturer, Qingmu’s products have been approved in China(DMF filed and listed on CDE’s website), and also submitted to USDMF, will apply CEP certificate in EDQM and MF in Japan PMDA soon, DMF in CTD format will be available and can be supported for the registration in worldwide.
  • Qingmu’s factory is established according to ICH/USFDA/EU/JAPAN/China regulations and current GMP, totally complies with environmental law in China, no risk to remove factory. A new API factory is under design and is predicted to be put into use in 2025.
  • Qingmu’s team has rich experience in patent challenges on crystalline form & synthesis processes and also synthetic route development and scale-up & quality research. Our company is committed to providing quality products and best services.
  • Qingmu’s lab is equipped with HPLC, GC, ICP-MS, GC-MS, CAD, microbalance, Malvern particle analyzer, etc. Qingmu passed the site inspection from NMPA(China), FDA(USA) and MFDS(Korea) and also customer audits from Europe, USA and Japan, etc.
  • Qingmu successfully exported products to more than 40 countries including Japan, USA, Germany, Spain, the Netherlands, Russia, South Korea, and Brazil.


A1: Yes if it’s listed on Pharmacopopeia, if not, we’ll establish our own standard according to USP/EP/JP/ChP

A2: One standard package during the commercial stage, but a sub-package can be arranged to support your development.

A3: Yes, it can be discussed.

A4: We support T/T, L/C, and DP.

A5: You can receive our reply within 24 hours if your inquiry was sent in working hours.

A6: Yes, we’re able to enlarge the batch size if current batch size couldn’t meet your requirement.